The DoLPHin Study: Hydroxocobalamin in PSC

The DoLPHin Study is an 8-week pilot study in the U.S., led by the Resnek Family Center for PSC Research at Brigham and Women's Hospital, testing the efficacy of a drug called hydroxocobalamin as a treatment for patients with PSC. All the study visits will take place remotely, and blood will be drawn by a research nurse who will visit the trial participants in their home.

The study team is looking to enroll adults 18 and over with PSC who have high alkaline phosphatase levels (>1.50 x the upper limit of normal) and who live in the U.S. Additional criteria apply; please check eligibility inclusion and exclusion criteria. To ensure eligibility, lab tests may be needed.

The goal of the DoLPHin Study is to determine the preferable dosing of hydroxocobalamin in patients with PSC. Twenty-eight patients will be enrolled into four successive groups in a crossover, placebo-controlled design. Patients will complete nine study visits over the course of up to 12 weeks. All study visits will be conducted by video/virtual visits or by a mobile research nurse, and a combination of blood tests, stool tests, urine tests, and questionnaires will be used to assess the effect of the drug over the course of the study.

The study team is looking to recruit 14 more patients to reach their recruitment goal. 

For further questions and interest in the study, please reach out to the study

coordinator directly via email at smitchell22@bwh.harvard.edu or via phone at

(508) 936-3674.